GEVO Gevo, Inc.
Industrial Organic Chemicals · Nasdaq · SEC CIK 1392380 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY80.1%
TTM net income YoY-303.6%
TTM EPS YoY-261.9%
Revenue 3-yr CAGR153.5%
Net income 3-yr CAGR—
Margins
Gross margin51.2%
Operating margin-68.2%
Net margin-83.7%
FCF margin-14.2%
EBITDA margin-56.5%
Returns
ROE-47.5%
ROA-29.7%
ROIC (approx.)-24.5%
Asset turnover0.36x
Leverage & solvency
Liabilities / assets42.9%
Debt / equity0.56x
Current ratio2.04x
Interest coverage-7.05x
Cash quality & payout
Operating cash flow / net income-0.18x
Accruals ratio-35.0%
Payout ratio—
Capex / revenue28.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $160.58M | $16.91M |
| Cost of revenue | $85.24M | $12.00M |
| Gross profit | $75.34M | $4.91M |
| R&D expense | $4.55M | $5.58M |
| SG&A expense | $51.20M | $45.80M |
| Operating income | -$20.21M | -$90.82M |
| Interest expense | $17.56M | $3.88M |
| Pretax income | -$32.63M | -$78.64M |
| Net income | -$33.84M | -$78.64M |
| EBITDA | $5.11M | -$72.53M |
| EPS (basic) | -0.14 | -0.34 |
| EPS (diluted) | -0.14 | -0.34 |
| Weighted avg. shares (diluted) | 234.01M | 231.67M |
| Balance sheet | ||
| Cash & equivalents | $81.16M | $259.03M |
| Receivables | $8.39M | $2.41M |
| Inventory | $19.08M | $4.50M |
| Current assets | $143.40M | $203.71M |
| PP&E, net | $353.58M | $221.64M |
| Goodwill | $43.56M | $3.74M |
| Intangibles | $95.00M | $8.13M |
| Total assets | $718.93M | $583.94M |
| Current liabilities | $78.58M | $24.36M |
| Short-term debt | $0 | $21,000 |
| Long-term debt | $164.75M | $67.11M |
| Total debt | $164.75M | $67.13M |
| Total liabilities | $247.76M | $94.45M |
| Shareholders' equity | $466.34M | $489.49M |
| Net debt | $83.59M | -$191.90M |
| Shares outstanding | 242.46M | 239.18M |
| Cash flow statement | ||
| Operating cash flow | -$13.40M | -$57.38M |
| Capital expenditure | $30.11M | $51.09M |
| Free cash flow | -$43.51M | -$108.47M |
| Investing cash flow | -$226.57M | -$51.82M |
| Financing cash flow | $97.88M | -$7.36M |
| Depreciation & amortization | $25.32M | $18.30M |
| Stock-based compensation | $9.21M | $14.73M |
| Share buybacks | — | $4.71M |
Free plan shows the latest 2 periods; Pro shows all 20 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.